Literature DB >> 2705568

Semiparametric approach to pharmacokinetic-pharmacodynamic data.

D Verotta1, S L Beal, L B Sheiner.   

Abstract

A semiparametric model for analysis of pharmacokinetic (PK) and pharmacodynamic (PD) data arising from non-steady-state experiments is presented. The model describes time lag between drug concentration in a sampling compartment, e.g., venous blood (Cv), and drug effect (E). If drug concentration at the effect site (Ce) equilibrates with arterial blood concentration (Ca) slower than with Cv, a non-steady-state experiment yields E vs. Cv data describing a counterclockwise hysteresis loop. If Ce equilibrates with Ca faster than with Cv, clockwise hysteresis is observed. To model hysteresis, a parametric model is proposed linking (unobserved) Ca to Cv with elimination rate constant kappa ov and also linking Ca to Ce with elimination rate constant kappa oe. When kappa oe is greater than (or less than) kappa ov clockwise (or counterclockwise) hysteresis occurs. Given kappa oe and kappa ov, numerical (constrained) deconvolution is used to obtain the disposition function of the arterial compartment (Ha), and convolution is used to calculate Ce given Ha. The values of kappa oe and kappa ov are chosen to collapse the hysteresis loops to single curves representing the Ce-E (steady-state) concentration-response curve. Simulations, and an application to real data, are reported.

Entities:  

Mesh:

Year:  1989        PMID: 2705568     DOI: 10.1152/ajpregu.1989.256.4.R1005

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  25 in total

1.  Pharmacokinetic-pharmacodynamic analysis of mnesic effects of lorazepam in healthy volunteers.

Authors:  O Blin; A Jacquet; S Callamand; E Jouve; M Habib; D Gayraud; A Durand; B Bruguerolle; P Pisano
Journal:  Br J Clin Pharmacol       Date:  1999-10       Impact factor: 4.335

2.  Influence of arterial vs. venous sampling site on nicotine tolerance model selection and parameter estimation.

Authors:  Franziska Schaedeli; Maria Pitsiu; Neal L Benowitz; Steven G Gourlay; Davide Verotta
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-02       Impact factor: 2.745

3.  Modeling nicotine arterial-venous differences to predict arterial concentrations and input based on venous measurements: application to smokeless tobacco and nicotine gum.

Authors:  Maria Pitsiu; Jean-Michel Gries; Neal Benowitz; Steven G Gourlay; Davide Verotta
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-08       Impact factor: 2.745

Review 4.  Biomarkers, validation and pharmacokinetic-pharmacodynamic modelling.

Authors:  Wayne A Colburn; Jean W Lee
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

5.  Quantification of tissue distribution of antibiotics by kinetic hysteresis analysis.

Authors:  U Ganzinger; K Neumann
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 6.  Pharmacodynamic modelling. Application to new drug development.

Authors:  P D Kroboth; V D Schmith; R B Smith
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

Review 7.  Pharmacokinetic-pharmacodynamic modelling: history and perspectives.

Authors:  Chantal Csajka; Davide Verotta
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-01-11       Impact factor: 2.745

8.  Estimation of amobarbital plasma-effect site equilibration kinetics. Relevance of polyexponential conductance functions.

Authors:  J W Mandema; P Veng-Pedersen; M Danhof
Journal:  J Pharmacokinet Biopharm       Date:  1991-12

9.  Use of Emax model in diuretic studies.

Authors:  F H Noormohamed
Journal:  Br J Clin Pharmacol       Date:  1990-12       Impact factor: 4.335

10.  A physiologically-based recirculatory meta-model for nasal fentanyl in man.

Authors:  Richard N Upton; David J R Foster; Lona L Christrup; Ola Dale; Kristin Moksnes; Lars Popper
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-08-19       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.